Trials / Completed
CompletedNCT00457613
Effects of Alkaline Phosphatase on Renal Function in Septic Patients
Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (planned)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Septic shock is the most common cause of death in patients requiring intensive care. The kidney is one of the first organs to fail, stressing the importance to search for clinical interventions that may protect the kidneys during sepsis. Alkaline phosphatase functions as a host defence molecule and is present in many cells and organs (e.g. intestine, placenta, liver, kidney and bone). Alkaline phosphatase has a dual mode of action. First, it binds to and, subsequently, dephosphorylates lipopolysaccharide (LPS). Second, the enzymatic reaction product monophosphoryl-LPS is a non-toxic substance for mammals which acts as a partial antagonist on the LPS receptor complex. In several animal studies, administration of alkaline phosphatase attenuates the inflammatory response and reduces mortality. It is unknown whether these results can be extrapolated to septic patients . We studied the effects of alkaline phosphatse administration on kidney damage and function in patients with severe sepsis or septic shock.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase) |
Timeline
- Start date
- 2004-11-01
- Completion
- 2006-03-01
- First posted
- 2007-04-06
- Last updated
- 2007-04-06
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00457613. Inclusion in this directory is not an endorsement.